Acadia Pharmaceuticals ACAD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $268.06M-5.6% | $283.99M+1.9% | $278.63M+5.3% | $264.57M+8.3% | $244.32M-5.9% | ||
| $24.79M-5.5% | $26.23M+21.1% | $21.65M+4.4% | $20.73M+1.7% | $20.39M-6.5% | ||
| $243.27M-5.6% | $257.76M+0.3% | $256.99M+5.4% | $243.83M+8.9% | $223.93M-5.8% | ||
| 90.8%0.0pp | 90.8%-1.5pp | 92.2%+0.1pp | 92.2%+0.5pp | 91.7%+0.1pp | ||
| $76.87M-9.3% | $84.76M-3.5% | $87.83M+12.7% | $77.95M-0.4% | $78.27M-22.3% | ||
| $171.02M+9.9% | $155.62M+16.7% | $133.4M-0.1% | $133.51M+5.6% | $126.37M-2.9% | ||
| $272.68M+2.3% | $266.6M+9.8% | $242.88M+4.6% | $232.19M+3.2% | $225.03M+112% | ||
| -$4.62M-127% | $17.39M-51.4% | $35.76M+10.4% | $32.37M+67.8% | $19.29M-87.4% | ||
| -1.7%-7.8pp | 6.1%-6.7pp | 12.8%+0.6pp | 12.2%+4.3pp | 7.9%-51.2pp | ||
| $8.06M-3.3% | $8.33M+1.0% | $8.25M+13.8% | $7.24M-8.3% | $7.9M+12.8% | ||
| $542K-9.1% | $596K+0.5% | $593K-0.2% | $594K+1.0% | $588K+2.3% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $3.98M-84.9% | $26.32M-41.0% | $44.6M+10.9% | $40.21M+44.8% | $27.78M-82.8% | ||
| $344K+100% | -$247.25M-810% | -$27.18M-301% | $13.55M+54.1% | $8.79M-49.3% | ||
| $3.64M-98.7% | $273.57M+281% | $71.78M+169% | $26.67M+40.4% | $18.99M-86.8% | ||
| 1.4%-95.0pp | 96.3%+70.6pp | 25.8%+15.7pp | 10.1%+2.3pp | 7.8%-47.6pp | ||
| $0.02-98.8% | $1.61+283% | $0.42+163% | $0.16+45.5% | $0.11-87.2% | ||
| $0.02-98.8% | $1.62+277% | $0.43+169% | $0.16+45.5% | $0.11-87.4% | ||
| 172.7M+1.6% | 169.9M-0.4% | 170.7M+1.2% | 168.7M+0.6% | 167.7M+0.8% | ||
| 170.5M+1.3% | 168.4M-0.3% | 168.8M+0.6% | 167.8M+0.6% | 166.8M+0.7% | ||
| $8.06M-3.3% | $8.33M+1.0% | $8.25M+13.8% | $7.24M-8.3% | $7.9M+12.8% | ||
| $271K+34.2% | $202K-11.0% | $227K+6.6% | $213K-7.0% | $229K+1.3% | ||
| —— | $6.29M0.0% | $6.29M0.0% | $6.29M0.0% | $6.29M+28.9% | ||
| $1.34M+112% | -$10.84M-757% | $1.65M-17.6% | $2M+5.2% | $1.9M+166% | ||
| $23.56M+134% | -$68.39M-346% | $27.78M+29.4% | $21.47M+18,605% | -$116K-100% | ||
| $32K-96.2% | $850K+21.4% | $700K-2.9% | $721K+23.2% | $585K— | ||
| -$6.5M-224% | $5.25M+136% | -$14.66M-271% | $8.59M+350% | $1.91M-30.2% | ||
| $542K-9.1% | $596K+0.5% | $593K-0.2% | $594K+1.0% | $588K+2.3% | ||
| $5.21M+30.1% | $4.01M+932% | $388K+30.6% | $297K— | $0-100% | ||
| $4.23M-81.3% | $22.67M+141% | $9.42M-40.9% | $15.96M+768% | $1.84M-6.7% | ||
| $86.5M-18.2% | $105.75M-15.8% | $125.59M-4.4% | $131.39M+0.5% | $130.8M+16.9% | ||
| $268.06M-5.6% | $283.99M+1.9% | $278.63M+5.3% | $264.57M+8.3% | $244.32M-5.9% | ||
| $14.7M+11.1% | $13.24M+0.4% | $13.18M-8.1% | $14.34M+26.0% | $11.38M+8.9% | ||
| -$4.62M-127% | $17.39M-51.4% | $35.76M+10.4% | $32.37M+67.8% | $19.29M-87.4% | ||
| -$1.62M-108% | $20.32M-47.5% | $38.71M+9.6% | $35.31M+58.8% | $22.24M-86.0% | ||
| -$1.62M-108% | $20.32M-47.5% | $38.71M+9.6% | $35.31M+58.8% | $22.24M-86.0% | ||
| -0.6%-7.8pp | 7.2%-6.7pp | 13.9%+0.5pp | 13.3%+4.2pp | 9.1%-52.0pp | ||
| -$4.62M-127% | $17.39M-51.4% | $35.76M+10.4% | $32.37M+67.8% | $19.29M-87.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Acadia Pharmaceuticals's profit margins?
- Gross margin is 91.5% and operating margin is 7.4%, with a 34.3% net margin.
- Where does Acadia Pharmaceuticals's income statement data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.